LOGIN
Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects
September 2018
Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
Clin Ther. 2007 Sep;29(9):2068-79Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Sixty-six patients from the UK with multiple sclerosis (MS) were enrolled in an initial 5-week, placebo-controlled RCT investigating the use of an oral-mucosal THC/CBD spray (Sativex). This study is an uncontrolled, open-label extension of the initial RCT, where all patients completing the initial RCT (n=64) were eligible to continue on the THC/CBD oral spray, and followed for 2-years. Sixty-three...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Join the Conversation
Please Login or Join to leave comments.